Indeed, in some of the AML patients, the expression level of SLC2A3 is higher, and when the contribution of SLC2A3 was considered in the overall survival of AML patients from the TARGET study, potential better survival effects were seen in patients with higher SLC2A3 expression (Fig. 5E) [42]. The gene discussed is SLC2A3; the disease is acute myeloid leukemia.